SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.
The live and archived webcast of the presentation will be accessible from the company’s website https://ir.structuretx.com/events-presentations/events. The replay of the webcast will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Contacts:
Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$20.12 |
Daily Change: | 1.59 8.58 |
Daily Volume: | 747,322 |
Market Cap: | US$1.160B |
August 06, 2025 May 08, 2025 February 27, 2025 December 17, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load